Axim Biotechnologies Inc (AXIM)

[HuskerGuy]

PRIORITIZING IN FOCUS AREAS, REDUCING OPERATING EXPENSES

In the short term, AXIM has identified the projects that have the
best chance to make it to market within 24-48 months, with
remaining initiatives moved to future development phases.

For current or upcoming Phase I trials, AXIM has selected:
1) MedChew™ with dronabinol, which targets treatment of
chemotherapy-induced nausea and vomiting and cachexia and lack
of appetite in HIV/AIDS patients and will undergo a bioequivalence
study as compared to FDA-approved Marinol®
2) MedChew™ RL which will undergo clinical trials as a potential
treatment for Restless Leg Syndrome (RLS)
3) MedChew Rx which will target treatment of pain and spasticity
associate with Multiple Sclerosis
4) CanChew™ Rx which aims to treat drug-induced psychosis.
These four clinical trial programs were selected due to the shorter
timeline and overall ability to bring the drugs to the market.
AXIM plans to maintain flat G&A costs in the short- and mid-term
clinical development phases.